Pharmacist and Director of MedResources.
Focused on trading pharma and biotech stocks. Also trade catalysts, special situations and earnings reports. I use leveraged ETFs to trade gold, silver, natural gas, and market trends.
I've been following the stock market for several years and have a particular interest in technology and biotech companies. I am not a registered financial advisor - my articles are for educational/entertainment purposed only.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
Individual investor with particular interest in any company that is on the cusp of change--for the better. These companies will have at least several attributes in common: They are underfollowed; underappreciated; have a clear, stated strategy for driving profits; management and BOD are perfectly aligned with common shareholders; management team and BOD with a track record of rewarding shareholders; and have near-term catalysts that will have meaningful impact on the business. Simple, right?
Long time traveler, 25+ countries so far, mostly for work which has been teaching in the last 18 years. Prior to that, international business, prior to that the performing arts. ..it's been quite a run! Relatively new to investing (old school!) but now need to if I'm ever going to plant myself somewhere to end out my years.